Loading…
ATHE
Alterity Therapeutics Ltd
NASDAQ· Healthcare· Biotechnology· CUSIP 02155X205
$4.51-1.10%Price as of Aug 29, 18:41 UTC · updated once a day, after the close
Key metrics
- Market cap
- $81.75M
- P/E
- —
- Forward P/E
- —
- P/B
- 0.0x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.58
- ROE
- -47.02%
- Profit margin
- -219.85%
- Revenue growth
- +74.60%
- Beta
- -0.04
- 52-week high
- $5.89
- 52-week low
- $2.66
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -69.9% over 5Y.
today you would have $288.98▼ -71.1%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 5 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|---|
| Year-end price | $3.67 | $3.08 | $3.31 | $2.49 | $3.50 | |
| P/B | 13.3x | 18.7x | 13.3x | 25.2x | 5.3x | 4.8x |
| EPS | -$1.33 | -$1.14 | -$3.14 | -$0.57 | -$3.18 | |
| ROE | -54.77% | -54.77% | -28.65% | -138.60% | -60.52% | -36.22% |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| SERASERA Prognostics Inc | $2.07 | — | 1.4x | — | -45.03% | $81.66M |
| ZYBTZhengye Biotechnology Holding Ltd | $1.73 | — | 2.2x | — | -25.17% | $81.99M |
| CTORCitius Oncology Inc | $0.78 | — | 2.0x | — | -126.58% | $82.03M |
| MAIAMAIA Biotechnology, Inc. | $1.33 |
About the company
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
- 9
- Melbourne, Australia
Company description provided by Yahoo Finance.